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2002 were obtained from Minnesota’s Department of Human
Services. Cost estimates include nursing and ancillary staff care,
as well as room and board. Costs are reported in 2002 US$.
RESULTS: Of the 3548 ischemic stroke cases identiﬁed in 1995,
618 qualiﬁed for analysis. Of those, 74% were female and the
mean age was 84 years (range: 37–102). The proportion of res-
idents in the low and medium dependency levels decreased from
37% to 22% over 6 years; whereas, the high dependency group
rose from 63% to 78%. In 2000, signiﬁcantly (p = 0.001) more
of the cohort was noted as physically and/or mentally incapable
of self-preservation than in 1995. On average, this increase in
care needs resulted in an additional annual cost of $3650 per
resident by the end of the 6-year period and roughly $2.25
million for the cohort. CONCLUSIONS: Stroke patients resid-
ing in nursing homes continue to deteriorate both physically and
mentally over time, resulting in increased care needs and costs.
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OBJECTIVES: A large proportion of patients with nonvalvular
atrial ﬁbrillation (NVAF) remain untreated with warfarin. We
aimed to compare survival and adverse outcome in patients with
NVAF treated with or without warfarin. METHODS: A number
of data sources were linked from a large population in the UK
from 1995 to 2000. Adverse events were characterised from
inpatient and death records. Survival was estimated using
Kaplan-Meier and Cox proportional hazards models, and com-
parisons between event rates using logistic or Poisson regression
and the Sign test. Patients were assumed to be receiving warfarin
if they had more than four INR measurements. RESULTS: We
identiﬁed 6108 patients with NVAF, of whom 36.4% received
warfarin. Mean survival in warfarin and non-warfarin groups
was 52.0 months and 38.2 months, respectively (p < 0.001), and
14.4 months (p < 0.001) after adjustment for confounding
factors. Warfarin patients in the upper quartile of INR control
had signiﬁcantly longer survival (57.5 months) compared with
those in the lowest quartile of control (38.1 months; p < 0.001).
The risk of stroke in the warfarin group when on treatment was
lower than that in the non-warfarin group (Relative Rate = 0.74,
p < 0.001). The risk of death from ischaemic stroke was lower
(RR = 0.43; p < 0.001) and there was a lower risk of all ischaemic
and embolic events (RR = 0.74; p < 0.001) in the warfarin group
when on treatment compared to the non-warfarin group. Risk
of bleeding in the warfarin group on treatment was greater com-
pared to the non-warfarin group (RR = 1.78; p = 0.001). CON-
CLUSIONS: These data suggest that failure to treat according to
guidelines in routine clinical practice, both in terms of patients
selected for anticoagulation and difﬁculty maintaining those
selected patients within the recommended target INR range of
2.0–3.0, is associated with additional mortality and morbidity in
patients with NVAF.
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OBJECTIVES: Recent re-pricing of the ritonovir (RTV) has 
been criticized as making the antiretroviral drug unaffordable.
These criticisms generally considered only cost and not cost-
effectiveness. Our study re-evaluates a previous cost-effectiveness
analysis of RTV while considering re-pricing. METHODS: A
previous cost-effectiveness analysis of HIV salvage regimens sug-
gested that therapy including RTV is cost-effective ($37,889 per
responding patient), although slightly less cost-effective than a
similar regimen using nelﬁnavir (NFV) ($31,476) (Becker R,
Shakur I, “Cost-effectiveness of salvage therapy with delavirdine
in NNRTI-naïve patients failing indinavir,” (abs.) Int. Conf. On
AIDS, Barcelona, Spain 2002.). Our present study applied 2003
drug prices for the two regimens (RTV + saquinivir [SQV] + ade-
fovir [ADV] and NFV + SQV + ADV) with and without delavir-
dine (DLV) to determine the total drug cost with each regimen.
The cost of RTV reﬂected recent re-pricing from $8.25 to $34.28
per dose. As with the previous study, results from the ACTG 359
trial were used to calculate the cost-effectiveness of the three-
drug regimens versus the four-drug regimens over a 48-week
timeframe. The results were compared to the earlier results and
sensitivity analyses were run. RESULTS: At 48 weeks, the 2003
cost-effectiveness of treating with a 4-drug combination includ-
ing RTV was $60,963 per responding patient. This reﬂects a
60.1% increase from the regimen’s incremental cost effectiveness
ratio (ICER) in the earlier study. In contrast, the four-drug com-
bination with NFV had an ICER of $34,310, or a 9.0% increase
over the combination’s ratio in the previous study. CONCLU-
SIONS: The re-pricing of RTV has a signiﬁcant impact on cost-
effectiveness analysis involving the drug. This analysis illustrates
that studies once showing RTV to be cost-effective may now
show less cost-effective compared to other regimens given
current prices. Other prior cost-effectiveness studies that
included RTV should be re-analyzed in light of the new pricing.
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OBJECTIVES: To investigate the net return to employers in the
UK of providing antiviral inﬂuenza treatment for their employ-
ees to reduce the impact of inﬂuenza epidemics on work par-
ticipation and productivity. METHODS: A probabilistic
decision-analytic model was developed to investigate the cost-
beneﬁt of providing inﬂuenza treatment compared to sympto-
matic treatment for a healthy adult working population (18–64
years) from the employer’s perspective. Data from clinical trials,
the literature and published UK sources were used. The human
capital approach, based on average income, was used to value
an employee’s work absenteeism due to illness. Characteristics
of ﬁrms and markets that determine how the gross beneﬁts of
reduced work absenteeism are distributed between employer and
employees are taken into account in one-way sensitivity analy-
ses additionally to the probabilistic framework. RESULTS: The
expected gross beneﬁt of reducing work absenteeism of £85.00
per treated employee outweighs the costs of providing inﬂuenza
treatment (£18.18), resulting in a net beneﬁt of £67.00. Sensi-
tivity analysis shows a net beneﬁt of £25.00 and a net cost of
£10.00 if the value of 1 day work loss is 50% and 10% of the
average salary respectively. If the actual work loss is only 30%
of the days to return to normal activity the intervention results
in a net beneﬁt of £13.00. However, if work loss is 30% of the
days to return to normal activity and the value of work loss is
